X

Drug Profile

BGB 53038

Alternative Names: BGB-53038

Latest Information Update: 19 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BeiGene
Class Antineoplastics
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

05 Sep 2024 BeiGene plans a phase Ia/Ib trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease), in December 2024 (NCT06585488)
13 Aug 2024 BGB 53038 is available for licensing as of 13 Aug 2024. https://www.beigene.com/about/partnering/
13 Aug 2024 Preclinical trials in Cancer in China (unspecified route) (BeiGene Pipeline, August 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com